TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01002183

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Fosmidomycin
Description: 450 mg capsules, every 12 hrs for 3 days
Study: NCT04771702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edmon
Description: Exhaled air will be analyzed for propofol
Study: NCT05062486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol, Quercetin, Curcumin (RQC)
Description: 100 mg resveratrol, 120 mg quercetin, 1000 mg curcumin BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: 1000 mg curcumin BID
Study: NCT04959162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-learning
Description: Development of theoretical knowledge using a E-learning platform before attending a hands-on course in musculoskeletal ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional preparation
Description: Attending a hands-on course in musculoskeletal ultrasound with no preparation before course start
Study: NCT05026060

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: 4-minutes eASL sequence without injection of contrast product added to each of the clinical MRs with standard ASL sequences performed for the care of the patient for 3 years.
Study: NCT04757974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 600 mg
Description: Fostemsavir tablets will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 600 mg
Description: Fostemsavir tablets will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 600 mg
Description: Fostemsavir tablets will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 600 mg
Description: Fostemsavir tablets will be administered via oral route.
Study: NCT05842018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab, Anlotinib and Chemotherapy
Description: Combination therapy:~Toripalimab 240mg will be intravenously administered on Day 1, Q3W; anlotinib: 12 mg qd d1-d14, d15-d21 discontinued, Q3W; investigator selected chemotherapy regimen (paclitaxel, pemetrexed or gemcitabine and other chemotherapeutic drugs which were not administered in the first-line therapy) for a total of 4 cycles.~Maintenance therapy:~After combination therapy, Patients who achieved complete response（CR）, partial response (PR), or stable disease (SD) were administered with toripalimab plus anlotinib as maintenance therapy. until disease progression or intolerable toxicity, treatment for 2 years, investigator decision, withdrawal of consent, or death.
Study: NCT06231979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1 μg/kg Dexmedetomidine per side in erector spinae block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 18 mL of bupivacaine 0.25 % per side in erector spinae block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 18 mL of bupivacaine 0.25 % per side in erector spinae block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 2 ml normal saline 0.9% per side in erector spinae block
Study: NCT05370833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Anodal, 2mA, tDCS session applied on M1 for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Anodal, 2mA, tDCS session applied on M1 for 20 minutes.
Study: NCT05458804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR training
Description: A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different paces and intensities of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
Study: NCT05238545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gluten-free diet
Description: Diet excluding foods containing gluten.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gluten-free diet
Description: Diet excluding foods containing gluten.
Study: NCT06026878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine,nimotuzumab, toripalimab
Description: same as before

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine, cisplatin
Description: same as before
Study: NCT05545683

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA 2001
Description: VLA2001 is a highly purified whole virus, inactivated, adjuvanted vaccine, using the manufacturing platform of Valneva's encephalitis (JE) vaccine
Study: NCT05720299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Akkermansia muciniphila
Description: 120 subjects were randomly assigned to ZY19 low-dose group, ZY19 high-dose group and placebo group at a ratio of 1:1:1. They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks) in ZY19 low-dose group, ZY19 high-dose group and placebo group respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Akkermansia muciniphila
Description: 120 subjects were randomly assigned to ZY19 low-dose group, ZY19 high-dose group and placebo group at a ratio of 1:1:1. They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks) in ZY19 low-dose group, ZY19 high-dose group and placebo group respectively.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment with placebo
Description: 120 subjects were randomly assigned to ZY19 low-dose group, ZY19 high-dose group and placebo group at a ratio of 1:1:1. They were treated with one bag of test drugs (one bag each time, twice a day, for 12 weeks) in ZY19 low-dose group, ZY19 high-dose group and placebo group respectively.
Study: NCT04757974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 600 mg
Description: Fostemsavir tablets will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 600 mg
Description: Fostemsavir tablets will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 200 mg
Description: Fostemsavir tablets will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 200 mg
Description: Fostemsavir tablets will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 200 mg
Description: Fostemsavir tablets will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 200 mg
Description: Fostemsavir tablets will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 200 mg
Description: Fostemsavir tablets will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 200 mg
Description: Fostemsavir tablets will be administered via oral route.
Study: NCT05112003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Translingual neurostimulation
Description: The device will be placed into and held in the participant's mouth for 20 minutes while the participant undergoes breathing and awareness training
Study: NCT05389033

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic bacteria
Description: 28 days daily supplementation with active probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: 28 days daily supplementation with placebo
Study: NCT05006482

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual follow-up survivorship care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Complete geriatric assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Participate in survivorship health education sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in EXCAP program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tailored Intervention
Description: Participate in GEM consultation
Study: NCT04757974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 200 mg
Description: Fostemsavir tablets will be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 200 mg
Description: Fostemsavir tablets will be administered via oral route.
Study: NCT05325021

Intervention type: DIAGNOSTIC_TEST
Intervention: Axial length measurement in millimeter (mm) by optical biometry device
Description: Axial length measurement of the anisometropic eye and the fellow one in millimeter (mm) by optical biometry device.

Intervention type: DIAGNOSTIC_TEST
Intervention: Axial length measurement in millimeter (mm) by optical biometry device
Description: Axial length measurement of the anisometropic eye and the fellow one in millimeter (mm) by optical biometry device.

Intervention type: DIAGNOSTIC_TEST
Intervention: Axial length measurement in millimeter (mm) by optical biometry device
Description: Axial length measurement of the anisometropic eye and the fellow one in millimeter (mm) by optical biometry device.

Intervention type: DIAGNOSTIC_TEST
Intervention: Axial length measurement in millimeter (mm) by optical biometry device
Description: Axial length measurement of the anisometropic eye and the fellow one in millimeter (mm) by optical biometry device.

Intervention type: DIAGNOSTIC_TEST
Intervention: Autorefractometer to measure the refractive error in both eyes.
Description: Measurement of the refractive state of both eyes for each subject to asses the refractive error in diopter (D).

Intervention type: DIAGNOSTIC_TEST
Intervention: Autorefractometer to measure the refractive error in both eyes.
Description: Measurement of the refractive state of both eyes for each subject to asses the refractive error in diopter (D).

Intervention type: DIAGNOSTIC_TEST
Intervention: Autorefractometer to measure the refractive error in both eyes.
Description: Measurement of the refractive state of both eyes for each subject to asses the refractive error in diopter (D).

Intervention type: DIAGNOSTIC_TEST
Intervention: Autorefractometer to measure the refractive error in both eyes.
Description: Measurement of the refractive state of both eyes for each subject to asses the refractive error in diopter (D).
Study: NCT03047239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Description: Smart contact lens based device indicated to detect the peak patterns of variation in intraocular pressure over a maximum period of 24 hours
Study: NCT06413238

Intervention type: DRUG
Group type: OTHER
Intervention: curcumin, saffron, Combination of saffron and curcumin and placebo
Description: This study investigates the individual and combined effects of curcumin and saffron on diabetes compared to a placebo group. It will assess the effects on both clinical and laboratory diabetes symptoms within and between groups. Participants will receive either two 500mg curcumin capsules in arm 1, one 15mg saffron capsule with a 500mg starch flour placebo in arm 2, one 500mg curcumin and one 15mg saffron capsule in arm 3, and two 500mg starch flour placebos in arm 4.

Intervention type: DRUG
Group type: OTHER
Intervention: curcumin, saffron, Combination of saffron and curcumin and placebo
Description: This study investigates the individual and combined effects of curcumin and saffron on diabetes compared to a placebo group. It will assess the effects on both clinical and laboratory diabetes symptoms within and between groups. Participants will receive either two 500mg curcumin capsules in arm 1, one 15mg saffron capsule with a 500mg starch flour placebo in arm 2, one 500mg curcumin and one 15mg saffron capsule in arm 3, and two 500mg starch flour placebos in arm 4.
Study: NCT05932186

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block combined with general anesthesia
Description: Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position. Interscalene block will be done as follows. US probe will be placed slightly lower to the level of the cricoid cartilage, followed by scanning of the neck to search for C5 and C6 nerve roots enclosed between the anterior and middle scalene muscles. The needle will be introduced in-plane from lateral to medial through the middle scalene muscle until the tip enters the brachial plexus sheath between the C5 and C6 roots, where LA will be injected.~Patients will be transported to the operation room where general anaesthesia will be induced with tracheal intubation Fentanyl (0.5 μg/kg) will be given to maintain the heart rate and mean blood pressure 20% lower than preinduction values. Intravenous 1 gram paracetamol and 8 mg dexamethasone will be given to all patients as part of multimodal analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper trunk brachial plexus block combined with general anesthesia
Description: Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position like the the ISB group~Upper trunk will be visualized distal to the convergence of the C5 and C6 nerve roots but proximal to the departure of the suprascapular nerve (This nerve is a small hypoechoic circle that depart the lateral aspect of the upper trunk and courses posterolateral under the omohyoid muscle). The needle will be introduced in-plane from lateral to medial under the deep cervical fascia and through a very small portion of the middle scalene muscle, until the needle tip lies adjacent to the upper trunk, LA will be distributed below and above the upper trunk. Scanning for the upper trunk can be started from the supraclavicular fossa and moving proximal or opposite to cricoid cartilage and moving distal.~The following steps will be done as in the ISB group
Study: NCT06413238

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: curcumin, saffron, Combination of saffron and curcumin and placebo
Description: This study investigates the individual and combined effects of curcumin and saffron on diabetes compared to a placebo group. It will assess the effects on both clinical and laboratory diabetes symptoms within and between groups. Participants will receive either two 500mg curcumin capsules in arm 1, one 15mg saffron capsule with a 500mg starch flour placebo in arm 2, one 500mg curcumin and one 15mg saffron capsule in arm 3, and two 500mg starch flour placebos in arm 4.

Intervention type: DRUG
Group type: OTHER
Intervention: curcumin, saffron, Combination of saffron and curcumin and placebo
Description: This study investigates the individual and combined effects of curcumin and saffron on diabetes compared to a placebo group. It will assess the effects on both clinical and laboratory diabetes symptoms within and between groups. Participants will receive either two 500mg curcumin capsules in arm 1, one 15mg saffron capsule with a 500mg starch flour placebo in arm 2, one 500mg curcumin and one 15mg saffron capsule in arm 3, and two 500mg starch flour placebos in arm 4.
Study: NCT05608811

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Skills Training
Description: Intervention:~The training is planned as 8 sessions. During this 4-week period, 2 sessions were held each week. The training, which will be held via Zoom, was carried out as a group or individual application. The first session was planned as four basic skills, the second session communication skills, the third session assertiveness skills, the fourth session conflict management skills, the fifth session social life skills, the sixth session friendship flirting skills, the seventh session health maintenance skills, and the eighth session professional/work skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: Intervention:~The training is planned as 8 sessions. During this 4-week period, 2 sessions were held each week. The training, which will be held via Zoom, was carried out as a group or individual application. The first session was planned as four basic skills, the second session communication skills, the third session assertiveness skills, the fourth session conflict management skills, the fifth session social life skills, the sixth session friendship flirting skills, the seventh session health maintenance skills, and the eighth session professional/work skills.
Study: NCT05062265

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tight rope fixation
Description: a traditional tight rope fixation is performed on one randomized set of subjects

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tight rope fixation with an anterior inferior tibiofibular ligament (AITFL) repair augmentation with an internal brace
Description: A tight rope fixation with an anterior inferior tibiofibular ligament (AITFL) repair augmentation with an internal brace set of subjects to compare syndesmotic volume
Study: NCT05929092

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Compared with peripheral blood stem cell transplantation (PBST), UCBT has a higher transplantation rate, as cord blood stem cells are more primitive. Since the first successful umbilical cord blood transplantation (UCBT) in a child with severe Fanconi anemia reported by Gluckman et al. in France in 1988, cord blood has been widely used as a graft source of hematopoietic stem cells for the treatment of hematological diseases. The first sibling UCBT for leukemia was performed successfully by Professor Yongping Song in China, who played a pioneering role in the development of UCBT for leukemia in China. On the basis of previous research, the TFBC regimen (TBI/Flu/Bu/Cy) combined with UCBT is safe and feasible for the treatment of patients with high-risk malignant hematological diseases, which has enormous potential to improve patient outcomes.
Study: NCT04847765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIPUN Gastric Monitoring System prototype
Description: The VIPUN Balloon Catheter prototype is a nasogastric feeding tube with integrated balloon that can be inflated with a preset volume of air. Intraballoon pressure changes are recorded outside the body. Gastric contractions can be detected in the pressure profile.~The recording lasts 30 minutes and is combined with simultaneous cine magnetic resonance imaging.
Study: NCT05736601

Intervention type: DEVICE
Intervention: focus motion knee brace
Description: knee brace that captures knee motion

Intervention type: DEVICE
Intervention: focus motion knee brace
Description: knee brace that captures knee motion
Study: NCT05222061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug coated balloon for the side brunch
Description: Intervention is explained in group description

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional balloon for the side brunch
Description: Intervention is explained in group description
Study: NCT05665296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervicothoracic mobilization
Description: Each participant in study group will receive cervicothoracic mobilization (central PA and transverse Grade III or grade IV) with comprehensive corrective exercise. The duration will eight weeks three sessions per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CCE
Description: Each participant will receive comprehensive corrective exercise include three phases: Initial phase -Improvement phase and Maintenance phase.~The initial phase exercises progress in frequency and intensity during this phase, as long as participants are able to demonstrate good quality movement. The initial phase duration is 2 weeks and the exercises will be performed for seven sets of 10-s hold .~Improvement phase exercises are progressed by considering individual characteristics of each participant and by observing the overload principle and the progression in the number of repetitions of each set during the 4 weeks of the improvement phase. The exercises will be performed from five sets of ten repetitions to six sets of 15 repetitions .~Maintenance phase exercises:The exercises are the same as in the improvement phase without any progression in intensity and frequency. The maintenance phase duration is 2 weeks
Study: NCT06045013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% dextrose injection
Description: Single ultrasound-guided injection of 4 ml 5% dextrose in carpal tunnel via ulnar approach.
Study: NCT05665296

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CCE
Description: Each participant will receive comprehensive corrective exercise include three phases: Initial phase -Improvement phase and Maintenance phase.~The initial phase exercises progress in frequency and intensity during this phase, as long as participants are able to demonstrate good quality movement. The initial phase duration is 2 weeks and the exercises will be performed for seven sets of 10-s hold .~Improvement phase exercises are progressed by considering individual characteristics of each participant and by observing the overload principle and the progression in the number of repetitions of each set during the 4 weeks of the improvement phase. The exercises will be performed from five sets of ten repetitions to six sets of 15 repetitions .~Maintenance phase exercises:The exercises are the same as in the improvement phase without any progression in intensity and frequency. The maintenance phase duration is 2 weeks